The sermorelin research record

The short version: what the studies found

The sermorelin research record is unusually rich for a peptide that currently has no approved finished formulation. The core human evidence covers three areas.

In children with growth hormone deficiency, once-daily subcutaneous injections roughly doubled the rate of height growth in the first year of a multicenter trial. In healthy older men, twice-daily doses restored GH and IGF-1 — a hormone the liver makes in response to GH — to levels seen in younger adults. In adults aged 55 to 87, a related GHRH analog taken nightly for 20 weeks improved executive function and reduced body fat in a randomized, placebo-controlled trial.

Beyond the pituitary, GHRH receptors appear in heart tissue, immune cells, and several other organs, which has opened a frontier of preclinical research on wound healing and other applications. All of that remains early-stage. The pages below trace each finding to its primary source.

Mechanism: the cAMP-PKA-CREB cascade

Sermorelin is the prototype of the GHRH-R agonist class. It binds the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on anterior-pituitary somatotroph cells. Receptor occupancy activates the heterotrimeric Gs protein; the α-subunit stimulates adenylyl cyclase; intracellular cAMP rises sharply; protein kinase A is activated; CREB is phosphorylated; and the somatotroph-specific transcription factor Pit-1 drives growth hormone gene transcription and secretion ^[13].

A 2025 review in Reviews in Endocrine and Metabolic Disorders maps the receptor's distribution carefully. GHRH-R is expressed not only on pituitary somatotrophs but also in myocardium, lymphocytes, testes, ovaries, skin, placenta, kidney, pancreas, and many human tumor tissues ^[13]. That distribution is what underlies the expanding research interest in GHRH-analog effects beyond pituitary GH release — cardiovascular, regenerative, immune, oncologic — even though sermorelin's own clinical record sits almost entirely in the pituitary-GH lane.

A 2024 Nature Reviews Endocrinology consolidation reinforces the same picture: sermorelin is the prototype of a drug class whose clinical scope is widening from somatotroph GH release into cancer, regenerative medicine, cardiovascular protection, and metabolic disease ^[16].

The pediatric efficacy record

The historic FDA approval rested principally on a multicenter international trial in prepubertal children with idiopathic growth hormone deficiency. Once-daily subcutaneous sermorelin at 30 µg/kg at bedtime increased mean height velocity from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months and 7.2 ± 1.3 cm/yr at twelve months. Seventy-four percent of children were classified as good responders at six months. No adverse changes in glucose homeostasis or in IGF-1 outside the expected range were observed ^[1].

A contemporary BioDrugs review of pediatric sermorelin practice concluded that the 30 µg/kg nightly regimen sustained height-velocity increases over twelve months and induced catch-up growth in the majority of prepubertal GHD children, with transient facial flushing and injection-site pain as the most common adverse events. Intravenous sermorelin at 1 µg/kg also functioned as a relatively specific provocative GH stimulation test, with fewer false positives than other stimulation modalities in the same review ^[2].

A separate trial extended the question to children with idiopathic short stature who did not meet classical GHD diagnostic criteria. GHRH(1-29)-NH2 treatment in this population produced a sustained increase in growth velocity — evidence that GHRH-R agonism augments the somatotropic axis even when baseline stimulation tests fall above the GHD threshold ^[5].

The adult aging-axis record

Two controlled studies anchor the adult somatopause literature:

Corpas and colleagues (1992) treated healthy older men (60-78 years) with 0.5 mg or 1.0 mg subcutaneous GHRH(1-29) twice daily for 14 days. The 1 mg dose restored mean 24-hour GH levels, peak GH amplitude, and IGF-1 concentrations to values not significantly different from healthy young men (22-33 years). Elevated IGF-1 persisted approximately two weeks after dosing stopped. No clinically significant changes in glucose, blood pressure, or routine laboratory values were recorded ^[3].

Khorram and colleagues (1997) dosed adults aged 55-71 (n=19) with nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg for 16 weeks after a 4-week placebo lead-in. Nocturnal GH and IGF-1 rose. Lean body mass increased by approximately 1.26 kg in men. Insulin sensitivity improved in men. Skin thickness — a dermal collagen marker — increased in both sexes. Subjective measures of well-being also improved ^[4].

These two trials are the canonical adult-somatopause GHRH(1-29) controlled studies. A 2025 clinical review of growth hormone and aging frames pulsatile, feedback-regulated GHRH stimulation as mechanistically distinct from continuous rhGH replacement and identifies pulsatility preservation as a key safety advantage in age-related research ^[15].

Cognitive trials in older adults

The most striking modern data come from a randomized placebo-controlled trial at the University of Washington. Baker and colleagues (2012) dosed 137 adults aged 55-87 — 76 healthy controls and 61 with mild cognitive impairment — with 1 mg of subcutaneous tesamorelin (a stabilized GHRH analog mechanistically analogous to sermorelin) nightly for 20 weeks. Executive function improved significantly (p = .005), with a trend toward improved verbal memory (p = .08). IGF-1 rose 117%. Body fat fell 7.4% ^[7].

A companion magnetic-resonance spectroscopy study by Friedman and colleagues (2013) probed the neurochemistry behind the cognitive findings. After 20 weeks of GHRH-analog dosing, GABA increased in all three brain regions assayed, N-acetylaspartylglutamate increased in the frontal cortex, and myo-inositol decreased in the posterior cingulate — a coherent pattern of neurochemical change consistent with the observed cognitive benefit ^[8].

A 2018 follow-on by Winston and colleagues looked at neuronal-derived exosomal biomarkers in the same trial population. Twenty weeks of GHRH-analog administration favorably modulated exosomal markers of synaptic and inflammatory pathways in adults with mild cognitive impairment, supporting a biological mechanism for the cognitive findings reported in the parent Baker trial ^[17].

The Baker and Friedman trials use tesamorelin rather than sermorelin proper. Tesamorelin is a stabilized GHRH analog that shares sermorelin's mechanism — same receptor, same downstream cascade — with a longer functional half-life. An earlier study by Vitiello and colleagues (2006) used GHRH(1-29) itself daily for 6 months in 89 healthy older adults and likewise reported improved executive function and global cognition, with the largest gains in subjects with lower baseline Mini-Mental State Examination scores ^[9].

Together the three studies establish — for a small but consistent body of evidence — that restoring the GH/IGF-1 axis in older adults via GHRH-R agonism can improve cognition in randomized, placebo-controlled designs.

Extrapituitary signaling and the wider analog class

GHRH-R is not only a pituitary receptor. Structurally related GHRH agonist analogs — MR-409, MR-356, JI-38 — have demonstrated cardioprotective effects after experimental myocardial infarction and accelerated dermal wound healing in animal models, driven by fibroblast proliferation and survival through ERK and AKT pathway activation ^[12].

A 2020 review of growth hormone secretagogues consolidates the mechanistic distinction between the GHRH-R agonist class (sermorelin, tesamorelin, CJC-1295) and the GHS-R/ghrelin-receptor agonist class (ipamorelin, GHRP-6, MK-0677). The two classes converge on the same somatotroph cell via independent intracellular pathways, which is why combined GHRH + GHS administration produces synergistic GH release greater than the additive sum of either alone — the pharmacologic basis underlying the common sermorelin + ipamorelin compounded co-administration pattern ^[16][14].

Regulatory state of play

A 2024 update on adult growth hormone deficiency syndrome documents how materially the post-2008 worldwide commercial unavailability of pharmaceutical GHRH has changed adult GHD diagnostic practice. The GHRH + arginine and GHRH + GHRP-6 stimulation tests, once standard, are no longer feasible through standard pharmaceutical channels in many jurisdictions — establishing the practical landscape in which compounded sermorelin is, for many U.S. clinicians, the only practical GHRH-class option that remains available ^[14].

The regulatory anchor for that practice is the FDA's March 2013 Federal Register determination (78 FR 14114), which formally established that the prior FDA-approved sermorelin acetate injection at 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp was not withdrawn from sale for reasons of safety or effectiveness ^[18]. That non-safety, non-efficacy finding is what permits 503A and 503B compounding pharmacies to prepare sermorelin from bulk substance under the FDA's interim 503A Bulks List Category 1 enforcement-discretion posture, pending final Pharmacy Compounding Advisory Committee review.